Watson up on favorable ruling

The drugmaker's shares jumped 4.2% to 68.20 after a federal court agreed with Watson Pharmaceuticals' (WPI) interpretation of Endo Pharmaceuticals' (ENDP) patent claim for its pain-killing patch Lidoderm. Watson is seeking FDA approval to make a generic version of Lidoderm. In Feb., Endo sued Watson for patent infringement. The trial is set to begin next year, but analysts now see Endo settling due to the ruling. Endo fell 1.8% to 39.01.